U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2001

[ ]  TRANSITION  REPORT UNDER SECTION 13 OR 15(d) OF THE  SECURITIES  EXCHANGE
     ACT OF 1934 FOR THE TRANSITION PERIOD FROM         TO


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

DELAWARE                                    98-0178784
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
incorporation or organization)


      #3-1482 Springfield Road, Kelowna, British Columbia, Canada  V1Y 5V3
                    (Address of principal executive offices)

                                  250.762.7552
                (Issuer's Telephone Number, including Area Code)



                              Thomas E. Stepp, Jr.
                                 Stepp Law Group
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has  been  subject to  such  filing  requirements for the past 90 days.  [x] Yes
[ ] No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date.  As of November 30, 2001, there were
6,096,889  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.



                                        1


<PAGE>













                                     PART I

Item 1. Financial Statements






                      Consolidated Financial Statements of


                      L.O.M. MEDICAL INTERNATIONAL INC.

                      (A Development Stage Enterprise)

                      Six months ended November 30, 2001

                      (Unaudited)
























                                        2


<PAGE>


<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Balance Sheets
$ United States

November 30, 2001 and May 31, 2001
-----------------------------------------------------------------------------------------------------------
                                                                           November 30,          May 31,
                                                                                   2001             2001
                                                                            (Unaudited)
-----------------------------------------------------------------------------------------------------------

<S>                                                                      <C>               <C>
Assets

Current assets
     Cash and cash equivalents                                           $      358,381    $     741,152
     Amounts receivable                                                           1,609           48,106
     Prepaid expenses                                                            10,201            1,455
-----------------------------------------------------------------------------------------------------------
                                                                                370,191          790,713

Advances and deposits                                                           163,915          161,415

Fixed assets                                                                     35,099           40,809

Patent costs                                                                      6,252            8,336

-----------------------------------------------------------------------------------------------------------
                                                                         $      575,457    $   1,001,273
-----------------------------------------------------------------------------------------------------------

Liabilities and Stockholders' Equity (Deficiency)

Current liabilities
     Accounts payable and accrued liabilities                            $      315,472    $     112,083

Minority interest                                                               280,182          301,727

Share subscriptions (note 2)                                                    148,865           22,100

Stockholders' equity (deficiency)
     Capital stock
       5,000,000 preferred shares with a par value of $0.001 per
         share authorized
       50,000,000 common shares with a par value of $0.001 per
         share authorized, 6,096,889 issued, net of treasury stock of
         100,933 (May 31, 2001 - nil) (May 31, 2001 -   6,152,811 issued)         6,097            6,154
     Additional paid-in capital                                               3,281,926        3,408,434
     Deficit accumulated during the development stage                        (3,490,389)      (2,882,529)
     Accumulated other comprehensive income                                      33,304           33,304
-----------------------------------------------------------------------------------------------------------
                                                                               (169,062)         565,363

-----------------------------------------------------------------------------------------------------------
                                                                         $      575,457    $   1,001,273
-----------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to consolidated financial statements



                                        3


<PAGE>


<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

Six months ended November 30, 2001 and 2000 and period from inception (March 17,
1997) to November 30, 2001
(Unaudited)

---------------------------------------------------------------------------------------------------
                                           From inception         Six months ended, November 30,
                                         (March 17, 1997)         ------------------------------
                                     to November 30, 2001               2001                2000
---------------------------------------------------------------------------------------------------

<S>                                    <C>                     <C>                 <C>
Expenses
     General and administration        $        2,356,826      $     235,777       $     214,557
     Research and development                   1,254,638            379,218             168,579
---------------------------------------------------------------------------------------------------
                                                3,611,464            614,995             383,136

---------------------------------------------------------------------------------------------------
Loss from operations                           (3,611,464)          (614,995)           (383,136)

Other income
     Interest income                              121,075              7,135              28,581

---------------------------------------------------------------------------------------------------
Loss                                   $       (3,490,389)      $   (607,860)       $   (354,555)
---------------------------------------------------------------------------------------------------


Weighted average number of shares,
   basic and diluted                            4,883,982          6,166,633           5,971,538

Loss per share, basic and diluted      $           (0.71)      $      (0.10)       $      (0.06)
---------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to consolidated financial statements



















                                        4


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

Three months ended November 30, 2001 and 2000
(Unaudited)

-------------------------------------------------------------------------------
                                                       2001             2000
-------------------------------------------------------------------------------

Expenses
     General and administration              $      150,712    $     106,342
     Research and development                       147,902           83,260
-------------------------------------------------------------------------------
                                                    298,614          189,602

-------------------------------------------------------------------------------
Loss from operations                               (298,614)        (189,602)

Other income
     Interest income (expense)                       (1,018)          14,922

-------------------------------------------------------------------------------
Net loss                                     $    (299,632)    $   (174,680)
-------------------------------------------------------------------------------


Weighted average common shares,
   basic and diluted                              6,180,606        6,034,358

Loss per common share, basic and diluted     $       (0.05)    $      (0.03)

-------------------------------------------------------------------------------

See accompanying notes to consolidated financial statements






















                                        5


<PAGE>


<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Cash Flows
($ United States)

Six months ended November 30, 2001 and 2000 and period from inception (March 17,
1997) to November 30, 2001
(Unaudited)

-------------------------------------------------------------------------------------------------------------------------------
                                                                       From inception          Six months ended November 30,
                                                                     (March 17, 1997)          -----------------------------
                                                                 to November 30, 2001               2001                2000
-------------------------------------------------------------------------------------------------------------------------------

<S>                                                                  <C>                   <C>                 <C>
Operating activities
   Net loss for the period                                           $    (3,490,389)      $   (607,860)       $   (354,555)

   Items not involving cash
     Amortization                                                             75,788              9,234               9,510
     Gain on sale of fixed assets                                             (2,659)                 -                   -
     Write down of product rights and patent costs                           374,128                  -                   -
     Compensation cost of stock options issued
       for services                                                          295,269                  -                   -
     Foreign exchange gain on redeemable preferred
       Shares                                                                (21,545)           (21,545)                  -

   Changes in non-cash working capital
     Amounts receivable                                                       (1,609)            46,497              (3,875)
     Prepaid expenses                                                        (10,201)            (8,746)             (5,173)
     Accounts payable and accrued liabilities                                315,472            (34,533)             (3,679)
-------------------------------------------------------------------------------------------------------------------------------
                                                                          (2,465,746)          (616,953)           (357,772)
Financing activities
     Issuance of capital stock                                             2,376,358            110,283             466,901
     Rescinded & cancelled shares                                           (258,948)           (21,026)                  -
     Proceeds from subscriptions for shares                                1,024,209            148,865             133,711
-------------------------------------------------------------------------------------------------------------------------------
                                                                           3,141,619            238,122             600,612
Investing activities
     Advances and deposits                                                  (163,915)            (2,500)            (75,395)
     Proceeds on disposition of fixed assets                                   6,189                  -                   -
     Acquisition of fixed assets                                            (102,670)            (1,440)             (5,244)
     Acquisition of product rights                                           (90,577)                 -                   -
-------------------------------------------------------------------------------------------------------------------------------
                                                                            (350,973)            (3,940)            (80,639)

Effects of change in exchange rates on cash and cash equivalents              33,481                  -                   -
-------------------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash and cash equivalents                             358,381           (382,771)            162,201

Cash and cash equivalents, beginning of period                                     -            741,152             959,318

-------------------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents, end of period                             $       358,381       $    358,381        $  1,121,519
-------------------------------------------------------------------------------------------------------------------------------

Supplementary information
   Interest paid                                                     $             -       $          -        $          -
   Income taxes paid                                                               -                  -                   -
Non-cash financing and investing activities
   Issuance of redeemable preferred shares for product rights                309,677                  -                   -
   Common shares issued for conversion of share subscriptions                875,344             22,100             185,513
   Compensation cost of stock options issued for services                    295,269                  -                   -
   Unpaid amount related to rescinded shares (note 3)                        236,922            236,922                   -
-------------------------------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying notes to consolidated financial statements


                                        6


<PAGE>


<TABLE>
<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated  Statement of Stockholders'  Equity  (deficiency) and Comprehensive
Loss
$ United States

Period from inception on March 17, 1997 to November 30, 2001

------------------------------------------------------------------------------------------------------------------------------
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated
                                             Number                Additional    During the           Other          Total
                                          of Common                   Paid in   Development   Comprehensive  Stockholders'
                                             Shares      Amount       Capital         Stage          Income         Equity
------------------------------------------------------------------------------------------------------------------------------

<S>                                       <C>          <C>        <C>          <C>             <C>            <C>
Common shares issued on incorporation             3    $      1   $         -  $         -     $          -   $         1

Comprehensive income (loss):
  Loss                                            -           -             -     (138,272)               -      (138,272)
  Foreign currency translation                    -           -             -            -           13,582        13,582
------------------------------------------------------------------------------------------------------------------------------
                                                                                                                 (124,690)

------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                             3           1             -     (138,272)          13,582      (124,689)

Common shares issued to founders
  and others at $0.001                    4,210,090       4,210             -            -                -         4,210

Common shares issued at $1.00
net of share issue costs                    668,154         668       469,887            -                -       470,555

Common shares issued at $1.00 on
  conversion of share subscriptions         605,000         605       604,395            -                -       605,000

Comprehensive income (loss):
  Loss                                            -           -             -     (293,239)               -      (293,239)
  Foreign currency translation                    -           -             -            -           (7,294)       (7,294)
------------------------------------------------------------------------------------------------------------------------------
                                                                                                                 (300,533)

------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998                     5,483,247       5,484     1,074,282     (431,511)           6,288       654,543

Common shares issued on
  November 30, 1998 at $3.25
  net of share issue costs                   36,300          36        96,726            -                -        96,762

Comprehensive income (loss):
  Loss                                            -           -             -     (726,055)               -      (726,055)
  Foreign currency translation                    -           -             -            -           17,038        17,038
------------------------------------------------------------------------------------------------------------------------------
                                                                                                                 (709,017)

------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999                     5,519,547       5,520     1,171,008   (1,157,566)          23,326        42,288

Common shares issued on
  April 17, 2000 at $3.25
  net of share issue costs                  307,610         308       967,335            -                -       967,643

Common shares issued on
  May 10, 2000 at $3.25 on
  conversion of share
  subscriptions                              19,302          19        62,712            -                -        62,731

Comprehensive income (loss):
  Loss                                            -           -             -     (508,835)               -      (508,835)
  Foreign currency translation                    -           -             -            -            9,978         9,978
------------------------------------------------------------------------------------------------------------------------------
                                                                                                                 (498,857)

------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2000                     5,846,459    $  5,847   $ 2,201,055  $(1,666,401)    $     33,304   $   573,805
------------------------------------------------------------------------------------------------------------------------------


                                        7


<PAGE>


<CAPTION>
L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated   Statements  of  Stockholders'  Equity  and  Comprehensive  Income
(continued)
$ United States

Period from inception on March 17, 1997 to November 30, 2001

------------------------------------------------------------------------------------------------------------------------------
                                              Capital Stock                         Deficit
                                         ----------------------                 Accumulated     Accumulated
                                             Number                Additional    During the           Other          Total
                                          of Common                   Paid in   Development   Comprehensive  Stockholders'
                                             Shares      Amount       Capital         Stage          Income         Equity
------------------------------------------------------------------------------------------------------------------------------

<S>                                       <C>          <C>        <C>          <C>             <C>            <C>
Balance, May 31, 2000,
  carried forward                         5,846,459    $  5,847   $ 2,201,055  $(1,666,401)    $     33,304   $   573,805

Common shares issued on
  September 22, 2000 for
  cash at $3.25 net of share
  issue costs                               249,271         250       726,654            -                -       726,904

Common shares issued on
  December 19, 2000 at $3.25
  on conversion of share
  subscriptions                              57,081          57       185,456            -                -       185,513

Compensation costs for
  stock options issued for
  services (note 5(b))                            -           -       295,269            -                -       295,269

Comprehensive loss:
  Loss                                            -           -             -   (1,216,128)               -    (1,216,128)
  Foreign currency translation                    -           -             -            -                -             -
------------------------------------------------------------------------------------------------------------------------------
                                                                                                               (1,216,128)

------------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2001                     6,152,811    $  6,154   $ 3,408,434  $(2,882,529)    $     33,304   $   565,363

Common shares issued on
  August 31, 2001 at $3.25
  on conversion of share
  subscriptions                               6,800           7        22,093            -                -        22,100

Common shares issued for cash
  on October 11, 2001 at $3.25               38,211          38       110,245            -                -       110,283

Comprehensive loss:
  Loss                                            -           -             -     (607,860)               -      (607,860)
  Foreign currency translation                    -           -             -            -                -             -
------------------------------------------------------------------------------------------------------------------------------
                                                                                                                 (607,860)
------------------------------------------------------------------------------------------------------------------------------
                                          6,197,822       6,198     3,540,773   (3,490,389)          33,304        89,886

Shares rescinded and retained
  as treasury stock (note 3)                (99,933)       (100)     (257,848)           -                -      (257,948)

Shares returned and retained
  as treasury stock (note 3)                 (1,000)         (1)         (999)           -                -        (1,000)
------------------------------------------------------------------------------------------------------------------------------
Balance, November 30, 2001                6,096,889    $  6,097   $ 3,281,926  $(3,490,389)    $     33,304   $  (169,062)
------------------------------------------------------------------------------------------------------------------------------
</TABLE>


                                       8


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited)

--------------------------------------------------------------------------------

L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation Laws of Delaware.  It conducts  research and development on
new products in the medical field  including a retractable  syringe.  Operations
effectively commenced on June 1, 1997.

1.   Significant accounting policies:

     a)   Going concern

          These  financial  statements  have been  prepared by management on the
          going concern basis in accordance with generally  accepted  accounting
          principles  in  the  United  States  of  America,  which  assumes  the
          realization of assets and  liquidation of liabilities  and commitments
          in the  normal  course  of  business.  As  shown  in the  consolidated
          financial  statements,  to date, the Company has generated no revenues
          and has  accumulated a deficit since  inception of  $3,490,389.  These
          factors,  among others,  raise  substantial  doubt about the Company's
          ability to  continue  as a going  concern.  The  Company's  ability to
          continue as a going  concern is  dependent  on its ability to generate
          future profitable  operations and receive continued  financial support
          from its stockholders and other investors.

          Management's  plans  with  respect  to  generating  future  profitable
          operations include future sales of the retractable  syringe as well as
          additional  funding from  stockholders in the form of additional share
          subscriptions.  There can be no  assurance  that a market will develop
          for the retractable  syringe or that additional  share financings will
          be  available.  Failure to obtain  adequate  financing  will cause the
          Company to curtail operations.

     b)   Basis of presentation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its wholly owned subsidiary. All significant inter-company
          balances and transactions have been eliminated.

          The financial  information  presented as at November 30, 2001, for the
          three and six  months  ended  November  30,  2001 and 2000 and for the
          period  from  inception  (March  17,  1997) to  November  30,  2001 is
          unaudited,  however,  in the opinion of  management,  all  adjustments
          (consisting  solely of normal  recurring items) necessary for the fair
          presentation of these unaudited  amounts in conformity with accounting
          principles  generally  accepted in the United  States of America  have
          been made. These unaudited interim  consolidated  financial statements
          should be read in conjunction with the annual  consolidated  financial
          statements for the year ended May 31, 2001 filed under Form 10-KSB.

     c)   Management estimates

          The preparation of financial  statements in conformity with accounting
          principles generally accepted in the United States of America requires
          management to make estimates and assumptions  that affect the reported
          amounts of assets and liabilities and disclosures of contingent assets
          and  liabilities  at the  date  of the  financial  statements  and the
          reported amounts of revenues and expenses during the reporting period.
          Actual results could differ from those estimates.



                                        9


<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited)

--------------------------------------------------------------------------------

2.   Share subscriptions

     During the six months ended  November 30, 2001 the Company  received  share
     subscriptions  for 5,020 common  shares at $3.25 per share for net proceeds
     of  $16,315  and  55,000  shares at $2.41 per  share  for net  proceeds  of
     $132,550.  The subscription  proceeds were received by the Company prior to
     December 1, 2001.


3.   Contingent liability:

     The  Company  has been  engaged in  discussions  with staff of the  British
     Columbia Securities  Commission (the "BCSC") concerning the distribution of
     the Company's common stock to certain residents of British Columbia.  Staff
     of the BCSC has taken the position that the  distribution of certain shares
     may not have,  in all  circumstances,  satisfied the  prospectus  exemption
     requirements  under the  Securities  Act  (British  Columbia).  In order to
     resolve the  concerns of staff of the BCSC,  the Company has agreed to make
     an offer of rescission (the "Rescission Offer") to purchasers of its common
     stock residing in British Columbia. The Company mailed the Rescission Offer
     in early August 2001 and such  Rescission  Offer was open for acceptance to
     November 30, 2001.  Under the Rescission  Offer, the recipient may elect to
     retain their shares in the Company or to rescind  their  original  purchase
     and return the shares to the  Company  and receive  from the  Company,  the
     purchase price  originally paid for the shares.  Stockholders  who acquired
     99,933   common   stock  from  the  Company  for   aggregate   proceeds  of
     approximately $257,948, exercised their right of rescission. As of November
     30,  2001 the  company  has paid  $21,026 of the  $257,948.  The  remaining
     $236,922 is included in  accounts  payable and accrued  liabilities  on the
     consolidated  balance sheet. These shares were being held in treasury as at
     November 30, 2001.

     During the six months ended November 30, 2001, a shareholder,  not entitled
     to the rescission offer,  holding 1,000 common shares with a cost of $1,000
     requested that the Company  accept the return of their shares.  The Company
     accepted  the return of the shares  and  repaid the  original  subscription
     price of  $1,000  to the  shareholder.  These  shares  were  being  held in
     treasury as at November 30, 2001.














                                       10


<PAGE>


Item 2. Management's Discussion and Analysis or Plan of Operation

THIS  ANNUAL  REPORT  SPECIFIES  FORWARD-LOOKING  STATEMENTS  OF OUR  MANAGEMENT
("FORWARD-LOOKING  STATEMENTS") INCLUDING,  WITHOUT LIMITATION,  FORWARD-LOOKING
STATEMENTS   REGARDING  OUR   EXPECTATIONS,   BELIEFS,   INTENTIONS  AND  FUTURE
STRATEGIES.   FORWARD-LOOKING   STATEMENTS  ARE  STATEMENTS  THAT  ESTIMATE  THE
HAPPENING   OF  FUTURE   EVENTS   AND  ARE  NOT  BASED  ON   HISTORICAL   FACTS.
FORWARD-LOOKING  STATEMENTS  MAY BE  IDENTIFIED  BY THE  USE OF  FORWARD-LOOKING
TERMINOLOGY,  SUCH AS "COULD",  "MAY", "WILL",  "EXPECT",  "SHALL",  "ESTIMATE",
"ANTICIPATE",  "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", "INTEND" OR SIMILAR
TERMS,   VARIATIONS  OF  THOSE  TERMS  OR  THE  NEGATIVE  OF  THOSE  TERMS.  THE
FORWARD-LOOKING  STATEMENTS  SPECIFIED IN THIS ANNUAL  REPORT ON FOR 10-KSB HAVE
BEEN COMPILED BY US ON THE BASIS OF ASSUMPTIONS  MADE BY US AND CONSIDERED BY US
TO BE  REASONABLE.  OUR FUTURE  OPERATING  RESULTS,  HOWEVER,  ARE IMPOSSIBLE TO
PREDICT AND NO  REPRESENTATION,  GUARANTY,  OR  WARRANTY IS TO BE INFERRED  FROM
THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE  FORWARD-LOOKING  STATEMENTS  REPRESENT
ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT TO UNCERTAINTY AS TO POSSIBLE CHANGES
IN ECONOMIC,  LEGISLATIVE,  INDUSTRY, AND OTHER CIRCUMSTANCES.  AS A RESULT, THE
IDENTIFICATION AND INTERPRETATION OF DATA AND OTHER INFORMATION AND THEIR USE IN
DEVELOPING  AND SELECTING  ASSUMPTIONS  FROM AND AMONG  REASONABLE  ALTERNATIVES
REQUIRE THE EXERCISE OF JUDGMENT.  TO THE EXTENT THAT THE ASSUMED  EVENTS DO NOT
OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY FROM ANTICIPATED OR PROJECTED RESULTS,
AND,  ACCORDINGLY,  NO  OPINION  IS  EXPRESSED  ON THE  ACHIEVABILITY  OF  THOSE
FORWARD-LOOKING   STATEMENTS.  NO  ASSURANCE  CAN  BE  GIVEN  THAT  ANY  OF  THE
ASSUMPTIONS RELATING TO THE FORWARD-LOOKING  STATEMENTS SPECIFIED IN THIS REPORT
ARE ACCURATE,  AND WE ASSUME NO  OBLIGATION  TO UPDATE ANY SUCH  FORWARD-LOOKING
STATEMENTS.

Our Development
---------------

L.O.M.  Medical  International Inc. was incorporated in the State of Delaware on
March 17, 1997. Our executive  offices are located at #3-1482  Springfield Road,
Kelowna, B. C., Canada V1Y 5V3. Our telephone number is 250.762.7552.

For purposes of  clarification,  all dollar amounts  specified in this Quarterly
Report of Form  10-QSB are  currency  of the United  States.  Anytime the symbol
"CDN" is used, it refers to the currency of Canada.

Our Business
------------

We were  incorporated for the purpose of researching and developing  health care
products.  Our goal is to become an  innovator  and  provider  of a  retractable
syringe  ("Syringe")  and related  products and  technologies to the health care
market.  We have  successfully  patented and  licensed  products in 70 countries
including the United States and Canada and continue to maintain  these  patents.
We plan to develop  new and  improved  products  and  provide  the  health  care
industry with better, safer products throughout the world.





                                       11


<PAGE>


The Retractable Syringe
-----------------------

We believe the Syringe will change standard disposal methods for used syringes.
The Syringe has been developed to function as a standard hypodermic syringe that
we believe is safer to the caregiver or health care worker. We believe that the
Syringe's unique design will allow health care providers to avoid direct contact
with used needles. The Syringe is covered by United States Patent No. 5,868,713
dated February 9, 1999, and international patents have been filed in 84
different countries.

Once the needle of the  Syringe is  injected,  the user  simply has to press the
plunger  top gently  with his or her thumb to  automatically  retract the needle
into its own sealed chamber. The needle is now hidden where it remains locked in
place and cannot be used  again.  The  Syringe  does not  require a health  care
worker  to use both  hands to  retract  the  needle  after it has been  used and
withdrawn  from the patient.  The Syringe will be produced in standard  industry
sizes from 1CC to 20 CC, inclusive.

We intend to promote  the Syringe as a safer and less  risk-oriented  instrument
for hospital  staff and health care  workers.  We are  optimistic  that doctors,
nurses,  and other health care workers will  recognize and appreciate the safety
features of the Syringe because of its ease of "use-and-disposal" and its unique
"contamination-prevention"  characteristics.  We currently  have no contracts to
sell the  Syringe  and  there  are no  guarantees  as to the  timing of any such
contracts in the future.

We anticipate that the products and technologies that we develop will be offered
to distributors on a worldwide basis, with an initial emphasis in Canada and the
United  States.  We hope  that our new  product  and  technology  ideas  will be
generated through active dialogues among our potential customers and our network
of  scientific   advisors.   We  also  hope  to   participate  in  national  and
international   conferences   and  generate   reviews  in  selected   scientific
literature.

We interact with a network of scientific advisors within the industry, including
members of academic institutions,  as well as potential customers. We anticipate
that these  relationships  will enable us to identify the  specialized  needs of
those potential  customers and provide  innovative and  commercially  acceptable
products and  technologies.  At this time,  our  relationships  with  scientific
advisors and academic  institutions  are limited to advisory  relationships.  We
anticipate  testing the Syringe in  conjunction  with teaching  universities  in
Canada, Britain, and other constituents of the United Kingdom.

Our engineering  personnel continue to perform design refinements  regarding the
Syringe,  and,  as a result,  we have been able to reduce  parts and enhance the
Syringe's gas cell.  This, in turn,  simplifies  the  manufacturing  and reduces
production  costs.  Patent  refinements  on the  Syringe  and  that gas cell are
constantly being filed weekly.

B.C.  Tech has  completed  95 % of its  contract to complete  production  of the
prototype Syringe,  as well as test units. We have received numerous  prototypes
from B.C. Tech for review and testing. This testing has resulted in enhancements
to the Syringe and more design changes.  These changes have delayed the delivery
of the remaining units of the initial  delivery of 5,000 units. We have received
200 units as of December 11, 2001.

We have contacted the Food and Drug Administration ("FDA"), and it has indicated
that we will not have to have a pre-market  approval  for the Syringe  before we
move to the next phase.

We will  continue  our  relationship  with B.C.  Tech Inc.  and Philips  Plastic
Corporation.  Currently  we have  molds  that will  produce  5,000  units of the
Syringe.  We are still within our budgeted  $400,000.00  for this work.  We have
started  interviewing  various companies that will be able to construct the next
series of molds for next 100,000 units.

We intend to satisfy our financial  obligations  pursuant to agreements to which
we are a party during the next few months from existing cash resources. From our
inception on March 17, 1997, to November 30, 2001,  we have incurred  $1,254,638
related  to the  development  of the  Syringe,  including  the proof of  concept
prototype and molds for the test syringes.


                                       12


<PAGE>


During the next 12 months, we plan to concentrate our efforts in the following:

     o    Perform design  refinements  on the Syringe,  in an effort to minimize
          parts and make manufacturing as simple and cost effective as possible;
     o    Selection of raw materials;
     o    Contact the FDA in anticipation of a 510K submission;
     o    Sterilization selection (E beam and Y beam); and
     o    Material compatibility.

During the next 12 months we anticipate increasing our staff as the prototype of
the Syringe moves  forward.  Dr. Simon Wood has agreed to supervise our research
and development  department.  Currently, he bills us on an hourly basis for work
completed.  There  is no  written  contract  with  him at  this  time.  We  have
contracted with Kevin Conway,  a mid-level  engineer for certain  services.  Mr.
Conway  performs  subcontract  work on an hourly  basis.  He is  assisting  with
CAD-CAM requirements relating to the development of the Syringe.

We are not currently  producing  commercial  quantities of products or currently
supplying any services to any third  parties.  No assurance can be given that we
will,  on a timely  basis,  be able to make the  transition  from  manufacturing
testing   quantities  of  the  Syringe  to  commercial   production   quantities
successfully or arrange for contract manufacturing.

We anticipate  contracting for the first 2 years of commercial production of the
Syringe. At the end of the second year of production,  we anticipate engaging in
significant  discussions  regarding the potential  regarding the construction of
our own production facility.  We recognize that the construction of a production
facility  will be  contingent  upon us  having  reached  our  sales  and  profit
projections.  Negotiations to establish manufacturing facilities in Ireland have
begun, but have not progressed beyond the preliminary discussions.

The Eye Care System
-------------------

We have  invented  and  developed an  insertion  and storage  device for contact
lenses ("Eye Care System"),  which is a method of handling and inserting contact
lenses.  We have  developed the following  components and solutions that will be
used together with the Eye Care System insertion and storage products:

     o    a  medical  inserter  that  will  remove  contact  lenses in a medical
          emergency situation for use by hospital medical staff and paramedics;
     o    disposable and replacement inserter ends;
     o    additional storage cups and caps; and
     o    all soaking and  disinfecting  solutions  that are to be used with the
          Eye Care System inserter.

The Eye Care  System is designed  so that the  practitioner  will no longer have
direct hand or finger contact with the contact lens when fitting the patient. We
believe  that  the  design  of the Eye  Care  System  will  reduce  the  risk of
contamination  and infection to the patient.  We have developed a liquid cleaner
for the Eye Care System that quickly cleans contact lenses. We have obtained FDA
approval for the Eye Care System product.

We have  completed  market testing and believe that the Eye Care System was well
received  at the  American  Optometrists  Association  convention  in  Montreal,
Canada,   where  approximately  30,000  units  were  distributed  to  opticians,
optometrists  and pharmacies.  We have completed the formulation of contact lens
solutions and copyrights  covering these products.  We have completed the design
and labeling of the Eye Care System.  We believe that the eye-care  products are
ready for marketing and distribution.

The target markets for the distribution for the Eye Care System product include,
but are not necessarily limited to hospitals and clinics, including optometrists
and opticians.


                                       13


<PAGE>


The Eye Care System products are currently produced in Canada. We own all of the
necessary  injection  molds.  We will contract for the  production of components
needed for the  assembly  and  packaging  of the Eye Care System  products.  The
actual assembly and packaging will be contracted with a third party.

We have produced 33,000 units of our eye care inserters,  which will be used for
demonstrations.  As such,  we have not recorded  those units as inventory on our
balance sheet, but recorded those units as expenses in our income statement,  as
net realizable value is anticipated to be nothing. We currently have the ability
to contract for the  production of commercial  quantities of our Eye Care System
products. We currently have dies with an output capacity of 150,000 units. There
is a second set of dies designed that will have a 300,000 unit  capacity,  which
would  allow  the  production  of a total of  450,000  units of Eye Care  System
products per month.

We have FDA  approval  to market  our line of eye care  products  in the  United
States and the  necessary  Canadian  approval  to market  eye-care  products  in
Canada.  We are reviewing various contracts with third parties to market the Eye
Care System in Canada, as well as the United States.

We continue to  concentrate  our  activities on the production and launch of the
Syringe.  When that is finalized,  we will  implement our marketing plan for the
Eye Care System products.

Skin Care Products
------------------

At this time we are reorganizing our approach to our skin care products. We will
not be pursuing this area aggressively until we are producing the Syringe.

Genetic Patents
---------------

We are currently  negotiating  licensing  agreements  with the owners of various
patents on genetic vectors. As of November 30, 2001, we have advanced $46,520 to
date to pay for patents.

Business of Our Subsidiary
--------------------------

There has been no activity by our subsidiary  this quarter.  We anticipate  that
for the foreseeable future our subsidiary will be inactive.

Future Capital Requirements
---------------------------

We will require additional cash to implement our business strategies,  including
cash for payment of increased  operating  expenses.  No assurance  can be given,
however,  that we will have access to the capital markets in the future, or that
financing will be available on acceptable terms to satisfy our cash requirements
necessary to  implement  our business  strategies.  The  inability to access the
capital markets or obtain  acceptable  financing  could have a material  adverse
effect on our results of operations and financial condition.

Our forecast of the period of time during which our financial  resources will be
adequate to support our operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could vary as a result of a number
of factors.

We anticipate  having to raise  additional  capital  during the next 3 months in
order to develop,  promote,  produce and distribute our proposed products.  Such
additional   capital  may  be  raised  through   additional  public  or  private
financings,  as well as  borrowings  and other  resources.  To the  extent  that
additional  capital  is  raised  from  the  sale  of  equity  or  equity-related
securities,  the  issuance of those  securities  could result in dilution of our
stockholders.

There can be no assurance that additional funding will be available on favorable
terms, if at all. If adequate funds are not available  within the next 3 months,
we may be required to curtail  operations  significantly  or to obtain  funds by


                                       14


<PAGE>


entering  into  arrangements  with  collaborative  partners  or others  that may
require us to  relinquish  rights to certain of our  products  that we would not
otherwise relinquish.

Business Risks
--------------

We are exposed to a variety of business risks, some of which are inherent to all
competitive commercial enterprises,  and others that are specific to the medical
products  industry.  We will  continue to endeavor  to limit all  specific  risk
factors by our operations and financial strategies.

Financial Risks
---------------

Our business  plans are  aggressive in nature.  Continued  rapid  expansion will
consume valuable working capital and result in significant  demand for cash from
operations  during  the next few  quarters.  We  expect  that  existing  capital
resources  and  contributions  from profits will not be  sufficient  to fund our
business plans as represented  without receiving  additional funds from external
sources.

Business Cycles and Risks of Cost Overruns
------------------------------------------

The  sale  and  implementation  of our  products  involve  a  reasonable  market
penetration.  Failure to secure reasonable market penetration could have adverse
effects on our business, results of operations and its financial condition.

Fluctuations in Financial Results
---------------------------------

Our operating  results will  fluctuate,  depending on factors such as the demand
for products,  the size and timing of contracts,  new products and enhancements,
price  competition,  changes in  operating  expenses and  personnel  and general
economic factors.  Therefore,  actual financial  results may vary  significantly
from those projected by us.

Third-Party Claims for Infringement
-----------------------------------

We are not aware that any of our products infringe on the proprietary  rights of
third parties.  There can be no assurance,  however, that third parties will not
claim such  infringements by us with respect to current or future products.  Any
such claims,  with or without merit,  could be time consuming,  result in costly
litigation, or cause product or shipment delays. Any of the foregoing could have
adverse effects on our business, results of operations or financial condition.

Dependence of Single Product Line
---------------------------------

Concentration  of sales in a single product line for the medical health industry
represents a substantial risk, should market conditions deteriorate.

Foreign Currency
----------------

Our business plans are primarily focused on the penetration in the United States
and subsequently worldwide markets; therefore, we will be subject to the risk of
foreign currency fluctuations.

Competition and Sales Channels
------------------------------

Several  companies  compete  with us in the  syringe  market and there are a few
competitors  in the safety syringe  market.  Most are  substantially  larger and
possess greater  financial  resources than we do. Our future  success,  however,
relies on achieving superior product development by greater concentration on the
needs of the market and faster response to evolving customer requirements. There
can be no  assurance,  however,  that  competitors  will  not  develop  products
superior to our products or achieve greater market  acceptance due to marketing,
sales channels or other factors.


                                       15


<PAGE>


Dependence on Large Distributors
--------------------------------

We will rely in part on business  partners for the distribution of our products.
This includes a few large  distributors in the United States. We may be impacted
by negative business cycles or events  experienced by these  distributors.  This
may result in a short or long term reduction in revenue.

Human Resource Risks and Growth
-------------------------------

Our  success is  largely  dependent  on the  performance  of its key  employees.
Failure to attract and retain key employees with necessary  skills could have an
adverse  impact upon our growth and  profitability.  Our business is expected to
increase  rapidly  during the next three  years.  This  increase  will result in
substantial  growth in the number of  employees,  the scope of our operating and
financial systems and the geographic area of our operations.  This increases the
responsibilities for both existing and new management personnel.  Our ability to
support the  projected  growth of our  business  will be  dependent  upon having
highly  trained  personnel  in place to conduct  pre-sales  activities,  product
implementation and other customer support services. Our future operating results
will  depend on the ability of our key  managers  and  employees  to continue to
implement and improve our operational,  customer support and financial  systems.
There can be no  assurance  that we will be able to manage any future  expansion
successfully,  and, if we cannot, this could adversely affect the results of our
operations and our financial condition.

Production and Quality Control
------------------------------

The manufacturing of products involves a number of steps and requires compliance
with  stringent  quality  control   specifications  imposed  on  us  by  various
regulators.  We may not be able to replace manufacturing capacity quickly, if we
were unable to use our manufacturing  facilities as a result of a fire,  natural
disaster (including  earthquake),  equipment failure or other difficulty,  or if
such  facilities  are  deemed not in  compliance  with the  various  regulators'
requirements  and  the  non-compliance  could  not  be  rapidly  rectified.  The
inability or reduced  capacity to  manufacture or have  manufactured  any of our
products  would have a material  adverse  effect on the  business and results of
operations.

Government Standards and Regulations
------------------------------------

Our  products  will be subject to  numerous  foreign  government  standards  and
regulations  that are  continually  being amended.  Although we will endeavor to
satisfy foreign  technical and regulatory  standards,  there can be no assurance
that our products will comply with foreign government standards and regulations,
or changes  thereto,  or that it will be cost effective to redesign our products
to  comply  with such  standards  or  regulations.  Our  inability  to design or
redesign products to comply with foreign standards could have a material adverse
effect on our business, financial condition and results of operations.

Product Liability Risk
----------------------

Our  business  and the  business of our  subsidiary  will expose us to potential
product  liability  risks that are  inherent in the testing,  manufacturing  and
marketing  of medical  products.  We do not  currently  have  product  liability
insurance,  and  there  can be no  assurance  that we will be able to  obtain or
maintain such insurance on acceptable terms or, if obtained, that such insurance
will provide adequate coverage against potential liabilities.

We face an inherent  business  risk of exposure to product  liability  and other
claims,  in the event that the  development or use of our technology or products
is alleged to have  resulted  in adverse  effects.  That risk  exists  even with
respect to those  products  that are  manufactured  in  licensed  and  regulated
facilities or that otherwise  possess  regulatory  approval for commercial sale.
There can be no  assurance  that we will  avoid  significant  product  liability
exposure.  There can be no  assurance  that  insurance  will be available in the
future on commercially  reasonable terms, or at all, or that such insurance will
be  adequate  to pay  potential  product  liability  claims  or  that a loss  of
insurance  or the  assertion  of a product  liability  claim or claims would not
materially  adversely  affect our business,  financial  condition and results of
operations.


                                       16


<PAGE>


Although  we have  taken,  and  will  continue  to  take,  what we  believe  are
appropriate  precautions,   there  can  be  no  assurance  that  we  will  avoid
significant  liability  exposure.  An  inability  to  obtain  product  liability
insurance at acceptable cost or to otherwise  protect against  potential product
liability claims could prevent or inhibit the commercialization of our products.
A product  liability claim could have a material adverse effect on our business,
financial condition and results of operations.

Liquidity
---------

We  believe we have  raised  enough  capital  to allow us to meet the  financial
obligations  for a period of at least 3 months from November 30, 2001.  However,
the forecast for the period of time during which the financial resources will be
adequate to support our operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could fail as a result of a number
of factors.

We had cash  resources of $358,381 at November 30, 2001. At May 31, 2001, we had
cash resources of $741,152.  At November 30, 2001,  total current assets of were
$398,764 and total current liabilities of $344,045.  At November 30, 2001, total
current assets exceeded total current  liabilities by $54,719.  At May 31, 2001,
total current assets were of $790,713 and total current liabilities of $112,083.
At May 31, 2001,  total current  assets  exceeded  total current  liabilities by
$678,630.  Because we are not generating any revenues,  our only external source
of  liquidity  is  the  sale  of our  capital  stock.  We  have  no  contractual
obligations for capital purchases or any other commitments.

Results of Operations
---------------------

We have not yet  realized  any  revenues  from  operations.  The net  loss  from
operations from March 17, 1997 (inception) to November 30, 2001, was $3,490,389.
The net loss for the 6-month  period  ended  November  30,  2001,  was  $607,860
compared to a loss of $354,555 for the 6-month  period ended  November 30, 2000.
The net loss for the 12-month  period ended May 31, 2001, was  $1,216,128.  Such
losses  were  primarily  the  result  of  product  development  and  operational
expenditures.

In the current 3 month  period the losses have  increased  compared to the prior
comparable  period  because we are now funding the  development  of the Syringe.
During the 6-month  period  ending  November 30, 2001, we have paid out $379,218
with  regards to  developing  the  Syringe,  including a  prototype  compared to
$168,579 incurred during the 6 months ending November 30, 2000. We have incurred
$64,259 in legal and accounting  fees for the 6-month period ending November 30,
2001  compared to $77,615 for the  6-month  period  ending  November  30,  2000.
Consulting  fees for the 6-month  period  ending  November 30, 2001 were $95,737
compared  to  $66,458  for  the  6-month   period  ending   November  30,  2000,
respectively.

For the 6-month  period ended  November 30, 2001,  capital stock and  additional
paid in capital have  decreased by $126,565  since May 31, 2001.  This is due to
our  rescission  of  shares of our  common  stock  for the  amount of  $257,948,
cancellation of $1,000 in shares of our common sock and additional shares issued
for the amount of  $110,283  this  quarter  and $22,100 for shares of our common
stock paid for last quarter and issued this quarter.


                                     Part II


Item 1. Legal Proceedings

Litigation Involving Our Subsidiary.
------------------------------------

Our subsidiary had been named in small claims court as a defendant in litigation
regarding  certain  architectural  drawings.  The  claim  relates  to  allegedly
excessive  charges  of  approximately  CDN  $5,000  that  was  invoiced  to  our
subsidiary without approval. The matter has been settled for CDN $13,000.


                                       17


<PAGE>


British Columbia Securities Commission Rescission Offer.
--------------------------------------------------------

As of November 30, 2001,  stockholders holding 99,933 shares of our common stock
with a paid up capital of $257,948 have exercised their right of rescission.  As
of November  30,  2001,  $21,026 had been paid by us  regarding  the  rescission
offer,  leaving  $236,922  remaining to be paid,  which has been recorded in our
accounts payable and accrued liabilities.

Item 2. Changes in Securities

Warrants.
---------

We have offered to all  shareholders  of record at June 30 2001, one warrant for
every 2 shares held by each  shareholder.  Each  warrant  entitles the holder of
such warrant to purchase one share of our common stock for $5.00 per share. Each
warrant  expires  by its own terms 90 days  after the first  transaction  in our
common stock occurs on a public market

Stock  Options.  Our Board of Directors  has adopted a stock option plan ("Stock
---------------
Option  Plan").  The Stock  Option  Plan is  designed  to retain  qualified  and
competent  officers,  employees  and  directors  of the  Company.  Our  Board of
Directors, or a committee thereof, shall administer the Stock Option Plan and is
authorized,  in its sole and absolute discretion, to grant options to all of our
eligible  employees,  officers  and  directors  (whether or not employed by us).
During  the year ended May 31,  2001,  340,417  stock  options  were  granted in
accordance  with the Stock Option Plan.  Under SFAS 123, a compensation  cost of
$295,269 has been  recorded for those  options  issued to  consultants.  Options
granted pursuant to the Stock Option Plan will be exercisable  within the period
specified in the respective stock option  agreements.  Options granted under the
Stock Option Plan will not be exercisable after the expiration of ten (10) years
from the date of grant for  shareholders  with less than 10%  ownership and five
(5) years for shareholders  with 10% or more share  ownership.  The Stock Option
Plan  will also  authorize  us to make  loans to  optionees  to  enable  them to
exercise their options.

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to Vote of Security Holders

None

Item 5.

Form 3 filed this quarter for Cliff Mandel, new director.

Item 6. Exhibits and Reports on Form 8-K

Form 8-K filed this quarter for Cliff Mandel as a new director.












                                       18


<PAGE>



                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Dated:   January 10, 2002                  L.O.M. Medical International, Inc.


                                        By:      _______________________________
                                                 John Klippenstein
                                        Its:     President






































                                       19